Master Alliance Provisions Guide (MAPGuide)

Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement

  • Information & materials sharing | Information sharing

Exhibit A

MoH and Pfizer will collaborate on analysis of the data points listen in this Exhibit A. MoH will provide Pfizer with the data specified in Exhibit B. 

Endpoints (beginning and ending dates to be mutually agreed by the Parties

  • Confirmed COVID-19 cases/week
  • Confirmed COVID-19 hospitalizations/week
  • Confirmed COVID-19 severe/ critical cases /week
  • Confirmed COVID-19 ventilator use/week
  • Confirmed COVID-19 deaths/weeks
  • Symptomatic cases/week
  • Weekly numbers of vaccines, as total by age and other demographic subgroups
  • Number of cases per week by age groups, and other demographic factors
  • Additional subgroup analyses and vaccine effectiveness analysis as agreed by the Parties

Additional potential analysis: Direct medical costs averted based on modeled impact of national vaccination program on outpatient visits, hospitalization, ICU admissions, etc.

Exhibit B: Data Transfer Requirements

MoH will transmit to PFIZER in electronic form aggregate pandemic data as described in this Exhibit. MoH will use a mutually agreeable electronic transmission method that protects the security and integrity of the data.

1. Status Reports

MoH will provide to PFIZER weekly data transfers that include the following information:

1.1 Epidemiological Data

Each data transfer will include, at a minimum, current counts of the following

  • Confirmed COVID-19 cases/week
  • Confirmed COVID-19 hospitalizations/week
  • Confirmed COVID-19 severe/critical cases /week
  • Confirmed COVID-19 ventilator use/week
  • Confirmed COVID-19 deaths/weeks
  • Symptomatic cases/week
  • Weekly numbers of vaccines, as total by age and other demographic subgroups
  • Number of cases per week by age groups, and other demographic factors

2. Ancillary Documents

Both Parties will provide to each other as needed the following Ancillary Documents:

2.1 If relevant an electronic “Data Dictionary” consisting of all data variable used, annotated with variable names and corresponding datasets;

2.2 documentation of statistical programming algorithms used to create the analysis datasets, methodologies used to convert source data into output (derived) data; and the relevant statistical analysis assumptions or plans; if needed to understand the datasets (e.g., Statistical Analysis Plan, List of Tables, programming plan); 

2.3 any other documentation as may reasonable be requested by either Party and mutually agreed upon by both Parties.

2.4 Transfer Schedule

MoH will transfer aggregate epidemiological data to PFIZER: (i) weekly; (ii) at the end of 1 year for any residual both Parties mutually agreed upon and other frequency mutually agreed upon. MoH will work with PFIZER if changes are needed in the data formatting or transmission process to ensure data quality and usability. Analysis of the data associated with the vaccination project will be independently or jointly performed by MOH and Pfizer and shared with the other Parties. Any analysis/results Pfizer may perform will be shared with the MOH to discuss and finalize jointly.